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Research
The environmental contaminant bisphenol 
A (BPA) is used in the production of poly-
carbonate plastics and epoxy resins. These 
products are used in many common consumer 
goods, such as food and drink containers, the 
lacquer lining of canned foods and drinks, 
infant formula bottles, office water coolers, 
sales receipts, and some dental sealants. Several 
recent studies (Brede et al. 2003; Howdeshell 
et al. 2003; Joskow et al. 2006; Kang et al. 
2003) have found that BPA can leach from 
these products during normal use. Recent 
reports show that ≥ 90% of the populations 
studied had detectable concentrations of BPA 
metabolites in the urine (Calafat et al. 2005, 
2008; Wolff et al. 2007). These studies have 
reported mean values of total urinary BPA to 
be 1–3 µg BPA/L urine, with values ranging 
from below the level of detection to > 100 µg 
BPA/L urine. Estimates of daily BPA intake 
based on models of BPA pharmacokinetics or 
exposure sources suggest that the mean adult 
is exposed to 0.4–1.4 µg BPA/kg body weight 
(BW), and the 95th percentile of exposure 
does not exceed 1.5–4.2 µg BPA/kg BW per 
day [Food and Agricultural Organization/
World Health Organization (FAO/WHO) 
2010; Lakind and Naiman 2008]. However, 
estimations of daily human exposure to BPA 
is a controversial subject that has recently been 
disputed (Taylor et al. 2011; Vandenberg et al. 
2007, 2010).
One concern over BPA stems from its clas-
sification as a xenoestrogen. BPA is reported 
to bind to the estrogen receptors (ER), albeit 
with an affinity several orders of magnitude 
less than estradiol, and induce downstream 
transcriptional activity (Kim et al. 2001; 
Krishnan et al. 1993; Kuiper et al. 1998). 
However, alternate targets of BPA action have 
recently been identified (Bouskine et al. 2009; 
Takayanagi et al. 2006; Takeshita et al. 2001), 
and the exact mechanism by which BPA func-
tions is currently unknown. Most of the litera-
ture has focused on the effects of short-term 
BPA exposure, administered during specific 
windows of early-life development, and the 
resultant later-life consequences. These stud-
ies have shown early-life exposure to BPA in 
female rodents alters the onset of puberty, dis-
rupts estrous cyclicity and normal mammary 
gland development, and increases the develop-
ment of preneoplastic lesions in the mammary 
gland, cell proliferation, and the incidence 
of mammary gland hyperplasia in transgenic 
mice lacking BRCA1 (Durando et al. 2007; 
Howdeshell et al. 1999; Jones et al. 2010; 
Markey et al. 2001, 2003; Munoz-de-Toro 
et al. 2005; Murray et al. 2007; Vandenberg 
et al. 2008; Wadia et al. 2007).
We have shown recently that oral BPA 
exposure during the prenatal period or pre-
pubertal period accelerates carcinogenesis in 
a model of chemically induced mammary 
cancer (Betancourt et al. 2010; Jenkins 
et al. 2009). Alterations to cell proliferation 
and apoptosis in the mammary gland were 
accompanied by molecular changes, includ-
ing increased expression and/or activation of 
the erbB family of receptor tyrosine kinases. 
These findings led us to hypothesize that a 
subpopulation of adults exist, namely women 
with HER2/erbB2-positive breast cancer, 
that could be negatively affected by chronic 
BPA exposure during adulthood. Women 
with breast cancer that overexpresses HER2/
erbB2 account for 15–30% of all diagnosed 
pathology subtypes and are usually associ-
ated with an unfavorable clinical outcome 
(reviewed by Barros et al. 2010).
Materials and Methods
Chemicals and antibodies. BPA was pur-
chased from Sigma Chemical Company 
(St. Louis, MO). Antibodies to epider-
mal growth factor receptor (EGFR), erbB2, 
phospho  rylatederbB3, phosphorylatederbB3, 
  insulin-like growth factor 1 receptor (IGF-1R), 
phosphorylated-IGF-1R, phosphorylated-
Bad, PI3K, PTEN, Akt 1, Akt 3, phospho-
rylatedAkt, glycogen synthase kinase-3-beta 
(GSK-3β), and phosphorylatedGSK-3β were 
purchased from Cell Signaling Technologies 
(Danvers, MA). Antibodies to erbB3 and 
IGF-1 were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA).
Animal care and use. Animal care and 
use were conducted according to established 
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Ba c k g r o u n d: Bisphenol A (BPA) is a synthetic compound used to produce plastics and epoxy 
  resins. BPA can leach from these products in appreciable amounts, resulting in nearly ubiquitous 
daily exposure to humans. Whether BPA is harmful to humans, especially when administered orally 
in concentrations relevant to humans, is a topic of debate.
oBjectives: In this study, we investigated the role of chronic oral exposure to BPA during 
adulthood on mammary carcinogenesis by using a transgenic mouse model that spontaneously 
develops tumors through overexpression of wild-type erbB2 [mouse mammary tumor virus 
(MMTV)-erbB2].
Me t h o d s : MMTV-erbB2 mice were exposed to 0, 2.5, 25, 250, or 2,500 µg BPA/L drinking water 
from 56 until 112 days of age (for mechanism of action) or 252 days of age (for tumorigenesis). 
Cellular and molecular mechanisms of BPA action in the mammary gland were investigated via 
immunohistochemistry and immunoblotting.
re s u l t s: Only low doses of BPA significantly decreased tumor latency and increased tumor multi-
plicity, tumor burden, and the incidence of metastasis. All BPA doses significantly increased the cell 
proliferation index, but only the higher doses also increased the apoptotic index in the mammary 
gland. At the molecular level, 25 µg BPA/L, but not 2,500 µg BPA/L, increased phosphorylation of 
erbB2, erbB3, insulin-like growth factor 1 receptor, and Akt in the mammary gland.
discussion: Low, but not high, BPA doses significantly accelerated mammary tumorigenesis and 
metastasis in MMTV-erbB2 mice. The combined ratio of cell proliferation and apoptosis indices 
and alterations in protein expression best predicted the ability of each dose of BPA to alter tumori-
genesis in this model.
key w o r d s : apoptosis, bisphenol A, BPA, mammary gland, MMTV-erbB2 mice, oral exposure, 
tumorigenesis. Environ Health Perspect 119:1604–1609 (2011). http://dx.doi.org/10.1289/
ehp.1103850 [Online 12 October 2011] Oral BPA increases mammary carcinogenesis and metastasis
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guidelines approved by the Institutional Animal 
Care and Use Committee at the University 
of Alabama at Birmingham. All animals were 
housed in a temperature-controlled facility 
with a 12-hr light/dark cycle. All animals were 
treated humanely and with regard for allevia-
tion of suffering. A colony of mouse mammary 
tumor virus (MMTV)-erbB2/neu transgenic 
mice [FVB/N-TgN(MMTV-neu202Mul)] was 
established through breeding pairs purchased 
from Jackson Laboratory (Bar Harbor, ME). 
Because progesterone and pregnancy have been 
reported to drive the MMTV promoter, only 
virgin female mice were used. Animals were 
fed AIN-76A diet (phytoestrogen-free; Dyets, 
Inc., Bethlehem, PA), housed in polypropylene 
cages, and provided glass water bottles.
Tumorigenesis. Female MMTV-erbB2 
mice were exposed to BPA via the drinking 
water, beginning at 56 days of age and continu-
ing for the lifetime of the animals (252 days of 
age). Cagen et al. (1999) and our own pre-
liminary data have shown BPA to be stable 
in water for 1 week. Water with and without 
BPA was supplied fresh weekly. The following 
treatment groups were set up: 0 (control) and 
2.5 (BPA2.5), 25 (BPA25), 250 (BPA250), 
and 2,500 (BPA2500) µg BPA/L drinking 
water (Figure 1). Drinking water of all groups, 
including the control group, contained 0.05% 
by volume of the vehicle, ethanol.
All animals were palpated twice weekly. 
Mice were sacrificed at 252 days of age or 
when tumors exceeded 10% BW. At sacrifice, 
animals underwent complete necropsy. All 
tumors, gross lesions, and lung sections were 
dissected and blocked in paraffin. Tumor vol-
ume was calculated by measuring the length, 
width, and height of the dissected tumor. All 
dissected tumors were pathologically graded 
according to the consensus statement of the 
Annapolis meeting of medical and veteri-
nary pathologists (Cardiff et al. 2000). Only 
those tumors classified as invasive mammary 
adenocarcinoma were used in the final analy-
sis of tumor latency (time to first, second, 
and third tumor), volume, and multiplicity. 
Quantification of lung metastases was deter-
mined through inflating the lungs with an 
India ink solution [15% vol/vol India ink, 
0.5% (vol/vol) ammonia solution]. Excised 
lesions as well as whole-lung sections were 
evaluated. All pathological analyses were car-
ried out under blinded conditions by a board-
certified pathologist (I.E).
Cell proliferation index. We selected 112 
days of age as the end point for mechanistic 
studies; at this age, no preneoplastic/neoplastic 
lesions were identified in the mammary glands 
of untreated mice in a preliminary ontogeny 
study (data not shown). At 112 days of age, the 
number four abdominal mammary glands were 
collected from MMTV-erbB2 mice treated 
with 0, 2.5, 25, 250, and 2,500 µg BPA/L 
drinking water. Tissue sections were depar-
affinized and rehydrated through xylene and 
graded alcohol washes. Slides were boiled in 
citrate buffer, incubated in hydrogen perox-
ide, and blocked using serum. The slides were 
incubated in Ki-67 primary antibody (Dako, 
Glostrup, Denmark) overnight in a humidified 
chamber. After incubating the tissue sections 
in the appropriate conjugated secondary anti-
body, we employed the ImmPRESS kit (Vector 
Laboratories, Burlingame, CA). Positively 
stained cells were visualized by incubating the 
tissue sections with 3,3´-diamonobenzidine 
(DAB) and counterstained with hematoxylin. 
Tissue sections were dehydrated with graded 
alcohols, cleared with xylene, and mounted 
with a glass coverslip. A minimum of 500 
mammary epithelial cells were counted from 
at least five different structures. All counts were 
performed in duplicate under blinded con-
ditions, with the final index for each section 
being a mean of the duplicate counts.
Apoptotic index. The index of apopto-
sis was determined through the use of the 
ApopTag Plus Peroxidase In Situ Apoptosis 
Detection kit (Chemicon International, 
Billerica, MA) according to the manufac-
turer’s protocol. Cells that stained positively 
and exhibited morphologic characteristics of 
apoptosis were counted as positive. A mini-
mum of 500 mammary epithelial cells were 
counted from at least five different structures. 
All counts were performed in duplicate under 
blinded conditions, with the final index for 
each section being a mean of the duplicate 
counts. A cell proliferation to apoptosis ratio 
was calculated for each individual gland.
Immunoblotting. Mammary glands were 
homogenized in RIPA lysis buffer (Pierce 
Biotechnolgy, Rockford, IL) with the use of a 
pestle and grinding kit (GE Healthcare Inc., 
Piscataway, NJ). Protein lysate was quantified 
using the Bradford assay (BioRad Laboratories, 
Hercules, CA). Equal protein content (40 µg) 
was loaded onto precast SDS Tris-HCl 4–20% 
polyacrylamide gels (BioRad Laboratories). 
Proteins were transferred to a nitrocellulose 
membrane overnight. The membrane was 
blocked and incubated in primary antibody. 
Secondary antibody and chemilume (Pierce 
Biotechnology) were added, and protein expres-
sion was visualized using film. Densitometry 
was assessed using Quantity One (BioRad 
Laboratories). Positive protein controls pur-
chased from the supplier of the corresponding 
antibodies and Kaleidoscope Precision Plus 
Protein standards (BioRad Laboratories) were 
employed to identify the protein of interest.
Statistical analysis. The statistical method 
for evaluating tumor latency was performed as 
previously described (Betancourt et al. 2010). 
Tumor multiplicity was analyzed using the 
Cochran–Armitage test. The incidence of 
pulmonary metastasis was compared using 
Fisher’s exact test. Normally distributed data 
were analyzed using analysis of variance fol-
lowed by Bonferroni’s multiple comparison 
test (MCT). Data not normally distributed 
were analyzed using the Kruskal–Wallis test 
followed by Dunn’s MCT.
Results
Oral exposure to low BPA doses alter mam-
mary tumorigenesis. Beginning at 56 days of 
age, female MMTV-erbB2 transgenic mice 
were exposed to BPA2.5, BPA25, BPA250, or 
BPA2500 via the drinking water. These doses of 
BPA allowed investigation of a broad range of 
BPA daily intake values, ranging from doses esti-
mated to be at human relevancy (BPA2.5 and 
BPA25) to exposures based on the existing regu-
latory daily intake limits of BPA in the United 
States (BPA250 and BPA2500) (Figure 1) 
(National Toxicology Program 1982).
Chronic consumption of low doses of 
BPA significantly accelerated several end 
Figure 1. Beginning at 56 days of age, female MMTV-erbB2 mice were provided 0, 2.5, 25, 250, or 2,500 µg 
BPA/L drinking water. Estimated daily intakes were calculated based on a 20-g mouse drinking 4 mL water 
daily. This is based on our preliminary study, which found that mice drink 4 mL water daily (unpublished 
pilot data). LOAEL, lowest observed adverse effect level.
BPA exposure
Sacriﬁce Treatment begins Birth
03 83 6
Weaning
Age
(weeks)
 T reatment  Estimated intake
Groups  (µg BPA/L)  (µg BPA/kg BW)  Signiﬁcance
Control (n = 94)  0  0  Baseline
BPA2.5 (n = 38)  2.5  0.5  Human relevant exposure
BPA25 (n = 76)  25  5  High human relevant exposure
BPA250 (n = 37)  250  50  EPA reference dose
BPA2500 (n = 36)  2,500  500  1% LOAELJenkins et al.
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points of mammary tumorigenesis in female 
MMTV-erbB2 transgenic mice. Both BPA2.5 
(p = 0.01) and BPA25 (p = 0.01) significantly 
increased tumor multiplicity, increasing the 
mean number of mammary tumors by 58% 
and 47%, respectively, compared with con-
trol (Figure 2A). The low doses of BPA also 
signifi  cantly reduced the median time to first 
tumor onset by at least 29 days compared with 
control (Figure 2B). The mean tumor volume 
was also significantly increased after chronic 
exposure to BPA25 (p < 0.05) and trended 
toward an increase with BPA2.5 treatment 
(Figure 2C). Further, chronic exposure to low 
doses of BPA significantly increased the num-
ber of mice that developed pulmonary metas-
tasis (Figure 2D). All of these effects were 
absent in the higher, regulatory-based doses of 
BPA. No significant differences between treat-
ments were noted for the location, incidence 
of necrosis, or the grade of the developing 
tumor (data not shown).
Overt markers of toxicity. Only BPA250 
significantly altered BW (Table 1). This 
alteration represents a loss in BW of < 10% 
compared with control; this BW loss failed 
to reach toxicological significance. Chronic 
BPA exposure also caused a slight increase in 
uterine wet weight and uterine wet weight to 
BW ratio, with BPA250 achieving statistical 
significance (Table 1).
Cellular proliferation and apoptosis in the 
mammary gland in response to BPA. At 112 
days of age, MMTV-erbB2 mice exposed to 
low BPA doses (BPA2.5 and BPA25) exhib-
ited a dose-dependent increase in the cell pro-
liferation index in mammary gland epithelial 
cells before plateauing at the higher doses 
(Figure 3A). BPA exposure also caused a dose-
dependent increase in the apoptotic index in 
mammary epithelial cells (Figure 3B). This 
resulted in the highest administered dose, 
BPA2500, having a significantly greater apop-
totic index compared with control. When 
cell proliferation and apoptosis were taken 
together to estimate cell turnover in mammary 
epithelial cells, the resultant cell proliferation 
to apoptosis ratio produced a non  linear dose–
response curve that closely mimicked the tum-
origenic response of MMTV-erbB2 mice after 
chronic exposure to BPA (Figure 3C). Both 
BPA2.5 and BPA25 resulted in cell prolifera-
tion to apoptosis ratios greater than control, 
with BPA25 achieving statistical significance. 
The higher doses of BPA administered in this 
study, BPA250 and BPA2500, did not differ 
significantly from control (Figure 3C).
Chronic BPA exposure alters the protein 
expression of signaling pathways involved in 
carcinogenesis. To determine whether oral 
exposure to BPA can interfere with the erbB 
and associated signaling pathways, we per-
formed targeted immunoblot analysis using 
mammary glands from 112-day-old MMTV-
erbB2 mice exposed to representative doses 
of BPA (Figure 4). BPA25 was selected from 
the low BPA doses because it altered all end 
points of tumorigenesis and resulted in the 
greatest disturbance of cell turnover compared 
with control. BPA2500 was selected from the 
high BPA doses because, despite not altering 
mammary tumorigenesis, it exhibited signifi-
cantly increased indices of cell proliferation 
and apoptosis.
To ensure that BPA did not accelerate 
tumorigenesis through driving the expres-
sion of the transgene, we first investigated the 
expression of erbB2 (Figure 4A). No differ-
ences were observed in the protein expression 
of erbB2 between any of the treatment groups. 
Despite this, exposure to BPA25, but not 
BPA2500, significantly increased the phos-
phorylation of erbB2 compared with control. 
Although BPA25 significantly decreased the 
expression of erbB3 compared with BPA2500-
treated mice, it significantly increased erbB3 
phosphorylation compared with control. The 
protein expression of EGFR (also known as 
erbB1) was not altered by any of the treat-
ment groups. Measuring the protein expres-
sion of the erbB ligand reported to be under 
the control of ER action, amphiregulin, we 
found a dose-dependent increase in protein 
expression. Accordingly, BPA2500 exhibited a 
significant increase in the expression of amphi-
regulin compared with control and BPA25. 
Chronic exposure to BPA25 significantly 
up-regulated the expression and phosphoryla-
tion of IGF-1R compared with control and 
BPA2500. We investigated the local expression 
of IGF-1R ligand, IGF-1, in the mammary 
gland as opposed to circulating values found 
in the serum. BPA25 treatment significantly 
increased the local mammary gland expression 
of IGF-1 ligand compared with control.
Next, we assessed the downstream Akt sig-
naling pathway (Figure 4B). The expression of 
PI3K and PTEN, which function as opposing 
gatekeepers for the activation of Akt, did not 
differ significantly between any of the treat-
ment groups at 112 days of age. BPA25 treat-
ment significantly increased the expression of 
the Akt 1 isoform compared with control and 
the Akt 3 isoform compared with BPA2500. 
Activation of Akt (pan-activation), as meas-
ured by phosphorylated Akt, was significantly 
up-regulated by BPA25 compared with con-
trol and BPA2500.
Figure 2. Tumor multiplicity (mean ± SE) (A), time-to-first-tumor latency as calculated from birth (B), tumor 
volume (mean ± SE) (C), and incidence of pulmonary metastasis (D) in MMTV-erbB2 transgenic mice after 
chronic oral intake of BPA through the drinking water. In B, p = 0.02 for BPA2.5, and p = 0.01 for BPA25, 
both compared with control. 
*p ≤ 0.05, and **p ≤ 0.01 compared with control.
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Table 1. The effects of chronic oral BPA on body and uterine weights.
Treatment BW (g) Uterine weight (mg) Uterine:BW ratio
Control 26.0 ± 0.3 90.2 ± 4.3 3.5 ± 0.2
BPA2.5 25.3 ± 0.6 100.7 ± 7.2 4.0 ± 0.3
BPA25 25.9 ± 0.4 107.3 ± 6.0 4.2 ± 0.2
BPA250 24.1 ± 0.2* 123.3 ± 13.6* 5.1 ± 0.6#
BPA2500 24.4 ± 0.3 113.0 ± 6.5 4.6 ± 0.3
BW, uterine wet weight, and uterine-to-BW ratio in 36-week-old MMTV-erbB2 mice after chronic oral exposure to BPA 
via drinking water. Values represent mean ± SE. 
*p ≤ 0.05, and #p ≤ 0.001 compared with control.Oral BPA increases mammary carcinogenesis and metastasis
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In addition, several downstream pro-
teins involved in this pathway were regulated, 
including GSK-3β, Bad, and the extracellu-
lar signal-regulated kinases (ERKs 1 and 2). 
Normally involved in the inhibition of glyco-
gen synthesis and tagging the oncogenic beta 
catenin for degradation, GSK-3β is phospho-
rylated and consequently inactivated by Akt. 
BPA25 significantly increased the phospho-
rylation of GSK-3β (inactive) compared with 
control and BPA2500. A slight, although sta-
tistically significant, increase in total GSK-3β 
protein expression was also noted in response 
to BPA25 compared with control and 
BPA2500. Bad, which normally functions as a 
pro-  apoptotic protein, also becomes inactivated 
when phosphorylated by Akt. BPA25 and 
BPA2500 significantly up-regulated the phos-
phorylation (inactivation) of Bad compared 
with control. The ERKs are involved in down-
stream signaling initiated by both the erbB 
and IGF family of receptor tyrosine kinases 
and have been shown to play integral roles in 
cellular prolifera  tion. The phosphorylation of 
ERK1 and ERK2 was up-regulated in response 
to BPA25, but not BPA2500, treatment.
Discussion
Despite several countries altering regula-
tions governing BPA intake in humans, limi-
tations in the United States have remained 
largely unchanged. This has been blamed on 
a lack of compelling evidence that BPA is 
capable of causing harm (European Food 
Safety Authority 2006; Food and Drug 
Administration 2008), citing study limita-
tions in the existing literature such as using 
inappropriate routes of administration, using 
a concentration range of doses that is too nar-
row, pursing end points not directly tied to 
pathology, and using statistically unsound 
sample sizes. Thus, the aim of this study was 
to evaluate the impact of chronic, oral BPA 
exposure during adulthood on the develop-
ment and progression of mammary carcino-
genesis while attempting to address some of 
the aforementioned deficits.
The doses of BPA administered in this 
study were selected with human applicabil-
ity in mind. Recent studies suggest that the 
average adult is exposed to low concentrations 
of BPA, no more than 0.4–1.5 µg BPA/kg 
BW per day (FAO/WHO 2010; Lakind and 
Naiman 2008). Further, the 95th percen-
tile of BPA exposure does not likely exceed 
1.5–4.2 µg BPA/kg BW per day. Our mice 
were exposed to 0, 2.5, 25, 250, or 2,500 µg 
BPA/L drinking water. Preliminary studies 
established a mean BW of 20 g and a daily 
intake of approximately 4 mL fluid. Thus, our 
doses resulted in the estimated daily consump-
tion of 0.5, 5, 50, and 500 µg BPA/kg BW, 
Figure 3. Proliferation index (A), apoptotic index (B), and cell proliferation-to-apoptosis ratio (C) in mammary gland epithelial cells of 112-day-old MMTV-erbB2 
mice treated ± chronic, oral BPA (n = 5–17 mice/treatment) via the drinking water. Values represent mean ± SE.
#p ≤ 0.001 compared with control.
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0
0.045
0.040
0.035
0.030
0.025
0.020
0.015
0.010
0.005
0
250
200
150
100
50
0
Control BPA2.5 BPA25
# #
#
#
#
BPA250 BPA2500 Control BPA2.5 BPA25 BPA250 BPA2500 Control BPA2.5 BPA25 BPA250 BPA2500
P
r
o
l
i
f
e
r
a
t
i
o
n
 
i
n
d
e
x
P
r
o
l
i
f
e
r
a
t
i
o
n
 
:
 
a
p
o
p
t
o
s
i
s
 
r
a
t
i
o
A
p
o
p
t
o
s
i
s
 
i
n
d
e
x
Figure 4. (A) Protein expression and/or phosphorylation of erbB2, phosphorylated-erbB2, erbB3, phos-
phorylated-erbB3, EGFR, amphiregulin, IGF-1, IGF-1R, and phosphorylated-IGF-1R in the mammary glands 
of MMTV-erbB2 mice exposed to 0 (control), 25 (low BPA), or 2,500 (high BPA) µg BPA/L drinking water 
(n = 6–8 mice/treatment). (B) Protein expression and/or phosphorylation of PI3K, PTEN, Akt 1, Akt 3, 
phosphorylated-Akt, GSK-3β, phosphorylated-GSK-3β, phosphorylated-Bad, phosphorylated-ERK1, and 
phosphorylated-ERK2 in the mammary glands. Graphs represent mean density ± SE as a percentage of 
the control. Representative blots for each of the proteins analyzed by immunoblots are included under the 
graphs (IGF-1 is excluded because it was quantitated via ELISA). For blot images, C, L, and H indicate rep-
resentative images from control, low BPA, and high BPA samples, respectively.
*≤ 0.05 compared with control; ##≤ 0.05 compared with BPA2500. 
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respectively. These doses of BPA allowed inves-
tigation of a broad range of BPA intake values, 
ranging from doses estimated to be of human 
relevancy (BPA2.5 and BPA25) to exposures 
based on daily regulatory intake limits of BPA 
in the United States (BPA250 and BPA2500). 
Future efforts should focus on validating these 
estimated intake values by measuring circulat-
ing serum BPA values.
Chronic administration of BPA resulted 
in a non  monotonic dose response for many 
of the tumorigenesis end points, with human-
relevant concentrations of BPA (BPA2.5 and 
BPA25) decreasing tumor latency and increas-
ing tumor multiplicity, tumor volume, and 
the incidence of metastasis. Although tumor 
grade did not differ significantly between 
treatment groups, significant increases in 
tumor volume and the incidence of metas-
tasis in mice chronically consuming human-
relevant concentrations of BPA support the 
recent study by Dairkee et al. (2008), which 
suggested that BPA may increase aggressive 
tumor formation. Furthermore, the reg-
ulatory-based concentrations (BPA250 and 
BPA2500) of BPA did not significantly alter 
any end point of the tumorigenesis study. 
These data suggest that chronic BPA con-
sumption during adulthood in MMTV-erbB2 
mice may function in a non  linear fashion for 
the development and progression of mam-
mary carcinogenesis. In this model, lower 
concentrations of BPA acted more potently 
than higher doses. Whether this pattern holds 
true in other animal models is not known and 
strongly warrants further investigation.
However, non  monotonic dose–response 
curves have been noted previously in the litera-
ture. Hugo et al. (2008) found that fat explants 
treated with BPA (0.1–10 nM) induced a 
U-shaped curve of adiponectin secretion, with 
low doses inhibiting and higher doses increas-
ing adiponectin secretion. Using IRC mice, 
Miyawaki et al. (2007) administered 1 or 10 µg 
BPA/L drinking water during perinatal devel-
opment. At the time of sacrifice, 1 µg, but not 
10 µg, BPA/L significantly increased adipose 
tissue weight and the concentration of circu-
lating serum leptin (Miyawaki et al. 2007). 
Considering that BPA has been described as 
a xenoestrogen, it is interesting to note that 
Vandenberg et al. (2006) found that mice 
exposed to estradiol exhibited a non  monotonic 
dose response for mammary gland morphology. 
Other classes of compounds, most notably the 
angiogenesis inhibitors, have also reported non-
monotonic therapeutic dose responses (Benelli 
et al. 2003; Bruns et al. 2004; Celik et al. 2005; 
Humar et al. 2002; Lalani et al. 2004; Motegi 
et al. 2002; Panigrahy et al. 2002; Slaton et al. 
1999; Tjin Tham Sjin et al. 2005, 2006; Trinh 
et al. 2000; Yamaguchi et al. 1999). Given that 
our data suggest a potential role for BPA in 
tumor angiogenesis because of the significant 
increases in tumor volume and the incidence of 
metastasis, future research efforts focusing on 
this connection are warranted.
We focused our attention on investi-
gating potential mechanisms behind the 
non  monotonic dose response in the MMTV-
erbB2 mouse. At the cellular level, chronic 
BPA administration during adulthood caused 
dose-dependent increases in cell prolifera-
tion and apoptosis indices in the mammary 
gland. Several studies investigating early-life 
exposure to BPA have reported similar results 
(Betancourt et al. 2010; Durando et al. 2007; 
Jenkins et al. 2009; Munoz-de-Toro et al. 
2005; Murray et al. 2007; Vandenberg et al. 
2008). When the cell proliferation indices 
and apoptotic indices were combined to pro-
duce an estimation of cell turnover in the 
mammary gland, a non  monotonic dose– 
response curve resulted. This non  monotonic 
dose–response curve was the best predictor 
of the ability of each concentration of BPA to 
alter tumorigenesis.
Our data suggest that the non  monotonic 
dose response observed for tumorigenesis is 
due, at least in part, to the differing ability of 
each concentration of BPA to induce apoptosis. 
All of the BPA doses studied were capable of 
increasing the cell proliferation index. However, 
only the higher doses of BPA were capable of 
countering the increased cell proliferation with a 
simultaneous increase in apoptosis in mammary 
gland epithelial cells. As a result, neither of the 
regulatory-based doses produced a ratio of cell 
turnover in the mammary gland that differed 
from controls. Conversely, without an increase 
in apoptosis, the lower doses of BPA resulted 
in a mammary gland where increased cell pro-
liferation was coupled to decreased apoptosis, 
skewing normal cell turnover and potentially 
contributing to carcinogenesis.
Our next aim was to determine which sig-
naling pathways may contribute to the ability 
of BPA to alter tumorigenesis. Using a repre-
sentative treatment group from each category 
of exposure, human relevant and regulatory 
based, we report distinct differences in pro-
tein expression and activation. The MMTV-
erbB2 transgenic mouse model is driven by the 
aberrant expression of the erbB2 growth factor 
receptor (Guy et al. 1992). Overexpression of 
other growth factor receptors, such as erbB3 
and IGF-1, and the downstream Akt pathway 
has also been reported to occur or contribute to 
carcinogenesis in this model (Kim et al. 2005; 
Pape-Ansorge et al. 2002; Siegel et al. 1999).
Neither low nor high exposure to BPA 
altered the protein expression of the transgene 
erbB2. However, the low BPA dose signifi-
cantly increased the phosphorylation of erbB2 
and erbB3, the expression and phosphory-
lation of the IGF-1R, and the local expres-
sion of IGF-1. The higher BPA dose did not 
significantly alter either the expression or 
phosphorylation of any of the receptors or 
ligands. The downstream signaling pathways 
of erbB2 are largely dictated by its receptor 
dimerization partner. The erbB3 receptor con-
tains six docking sites for PIP3, which serves 
as a docking site of the serine kinase Akt. 
Heterodimerization between erbB2 and erbB3 
has been reported to preferentially induce the 
activation of the Akt pathway. Thus, with 
BPA25 significantly increasing erbB2 and 
erbB3 phosphorylation, it was not surprising to 
find that it also increased Akt isoform expres-
sion and phosphorylation. Again, these effects 
were absent in the BPA2500 treatment group. 
Collectively, our results suggest biologically dis-
tinct mechanisms for BPA that differ according 
to the dose administered. Further, the data 
presented here suggest that aberrant signaling 
in the erbB and IGF signaling pathways may 
play a role in the detrimental effects of low-
dose BPA.
Conclusions
The data presented here provide the first evi-
dence that oral administration of BPA affects 
cancer development and progression in a non-
monotonic fashion. Our research supports 
that differing doses of BPA may function in 
distinctly different, sometimes opposing, man-
ners at both the tissue and molecular level. 
That these data are derived from a genetically 
distinct model (MMTV-erbB2 mouse) may be 
a compelling concern for a population at risk, 
that is, women with HER2/neu overexpress-
ing breast cancer, who account for 15–30% 
of all women diagnosed with breast cancer. 
Although no model is a perfect predictor of 
human disease, the MMTV-erbB2 mice were 
selected over comparable models for several 
reasons. Most important, this provides a model 
that exhibits a) histopathological development 
that is similar to humans, b) clinically relevant 
molecular cancer subtype, c) lengthy tumor 
latency, d) low tumor multiplicity, and e) high 
incidence of pulmonary metastasis (Di Carlo 
et al. 1999; Guy et al. 1992). Although data 
obtained in animals may not translate per-
fectly to humans, the data presented here do 
cause some concern for the current conditions 
of BPA use, exposure, and regulation. Future 
research should pursue whether these findings 
can be replicated in other modeling systems of 
differing tumor pathologies.
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